Plasma Fractionation Market Summary
As per MRFR Analysis, the Plasma Fractionation Market was valued at 22.7 USD Billion in 2023 and is projected to grow to 37.5 USD Billion by 2035, with a CAGR of 4.28% from 2025 to 2035. The market is driven by increasing demand for immunoglobulin therapy, technological advancements, and rising prevalence of chronic diseases. Key players are investing in production facilities and regulatory approvals, particularly in underserved markets, enhancing access to plasma-derived therapies.
Key Market Trends & Highlights
The Global Plasma Fractionation Market is witnessing significant trends driven by healthcare demands and technological innovations.
- Immunoglobulin segment expected to dominate with a valuation of 10.5 USD Billion in 2024, growing to 18.0 USD Billion by 2035.
- North America market valued at 10.5 USD Billion in 2024, projected to reach 17.5 USD Billion by 2035.
- Rising investment in healthcare infrastructure, with the U.S. allocating over 10% of its GDP to healthcare expenditures.
Market Size & Forecast
2023 Market Size: USD 22.7 Billion
2024 Market Size: USD 23.66 Billion
2035 Market Size: USD 37.5 Billion
CAGR (2025-2035): 4.28%
Largest Regional Market Share in 2024: North America.
Major Players
Key companies include Octapharma, CSL Behring, Pfizer, Kedrion, Takeda Pharmaceutical, Grifols, and Baxter International.
Key Plasma Fractionation Market Trends Highlighted
The Plasma Fractionation Market is experiencing significant growth driven by the increasing demand for immunoglobulins for the treatment of various diseases, particularly in the fields of immunology and hematology.
As countries continue to prioritize healthcare expenditures, the need for effective therapies derived from human plasma has surged, fostering advancements in technology and production capabilities.
Moreover, the rise in lifestyle-related diseases, along with an aging population, has heightened the reliance on plasma-derived products to meet therapeutic needs. Presently, there are several opportunities that could be explored within the Plasma Fractionation Market.
The ongoing expansion of biopharmaceutical companies and research institutions looking to enhance their product offerings presents a chance for increased collaboration and innovation. Additionally, investing in research and development to improve plasma collection and fractionation techniques can lead to more efficient manufacturing processes.
This may ensure a steady supply of high-quality plasma products while addressing potential shortages caused by growing demand. Recent trends indicate a shift towards more stringent regulatory frameworks across the globe, compelling manufacturers to comply with higher safety and quality standards in their products.
This has led to a greater emphasis on automation and integrated systems within facilities, optimizing the production process while ensuring product integrity. Furthermore, increased awareness around the therapeutic benefits of plasma proteins has catalyzed growth opportunities in emerging markets.
As nations aim to bolster their healthcare systems, there is a strong potential for investment in plasma fractionation technologies, setting the stage for a dynamic and competitive market landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Plasma Fractionation Market Drivers
Rising Demand for Immunoglobulin Therapies
The Plasma Fractionation Market Industry is seeing a considerable increase in demand for immunoglobulin therapy, which is essential for treating a variety of immunodeficiency illnesses. According to the World Health Organization (WHO), more than 80% of individuals with primary immunodeficiency diseases (PID) require immunoglobulin replacement treatment.
With an estimated 80% rise in detected cases over the previous decade, owing to improved diagnostic procedures, groups such as the Plasma Protein Therapeutics Association (PPTA) are campaigning for greater access to these treatments.
Notably, the rise in immunoglobulin therapy highlights the importance of efficient plasma fractionation processes, putting leading companies like CSL Behring and Grifols ahead of the curve by investing in advanced manufacturing technologies and optimizing production capabilities to meet this growing demand.
Increasing Prevalence of Hematological Disorders
The Plasma Fractionation Market Industry is positively influenced by the growing prevalence of hematological disorders such as hemophilia and multiple myeloma.
According to the World Federation of Hemophilia, there are approximately 400,000 known cases of hemophilia worldwide, with a notable increase of 10% over the past five years due to enhanced reporting and increased awareness of the disorder.
This escalation drives the need for plasma-derived clotting factors, which necessitates the advancement of plasma fractionation techniques.
As market leaders like Takeda Pharmaceutical Company invest in Research and Development initiatives to enhance the efficacy of plasma-derived medications, the industry is expected to thrive in response to these healthcare challenges.
Growing Investments in Research and Development
The Plasma Fractionation Market Industry is benefiting from significant investments in Research and Development (R&D) aimed at innovation in plasma collection and fractionation technologies.
According to the European Medicines Agency (EMA), there has been a 25% increase in R&D investments related to plasma-derived therapies over the last five years, driven by collaboration between academic institutions and biopharmaceutical companies.
Companies like Octapharma and Baxter International have been pivotal in fostering these advancements, leading to the development of novel therapies and efficient processing methods.
Such investments not only augment the therapeutic options available but also enhance the manufacturing process of plasma products, subsequently expanding the Plasma Fractionation Market.
Plasma Fractionation Market Segment Insights
Plasma Fractionation Market Application Insights Â
The Plasma Fractionation Market is witnessing substantial growth across various applications, reflecting its significance in the healthcare industry, particularly in the fields of Neurology, Hematology, General Medicine, and Immunology. In 2024, the market is projected to be valued at 23.66 USD Billion, with applications playing a crucial role in driving this growth. Among the applications, Hematology and General Medicine are significant contributors, demonstrating majority holdings in market value.
Hematology is anticipated to reach 6.8 USD Billion in 2024 before growing to 10.5 USD Billion by 2035, indicating the demand for plasma-derived products in the management of blood disorders. General Medicine is also expected to show considerable growth, starting at 8.9 USD Billion in 2024 and increasing to 13.8 USD Billion by 2035.
This reflects the essential role plasma fractionation plays in treating various conditions, from immune disorders to infections.On the other hand, Neurology is another pivotal application, valued at 5.5 USD Billion in 2024, with expectations to rise to 8.7 USD Billion by 2035.
This indicates a growing recognition of the essential contributions of plasma-derived therapies in treating neurological disorders, which often require specialized treatments not fully addressed by conventional medicine. The Immunology application, while smaller, stands at 2.46 USD Billion in 2024 and is projected to reach 4.5 USD Billion by 2035. The growth in this area is crucial as plasma products play a vital role in immune system support and treatment of autoimmune diseases, thus highlighting its significance in patient care.
Overall, these figures signal a strong market growth trend driven by increasing healthcare needs and advancements in plasma fractionation technology. Additionally, market growth is supported by a rise in chronic diseases and an aging population, contributing to the increasing demand for plasma-derived therapies.
There are ample opportunities for innovation and development within the Plasma Fractionation Market, especially as research continues to uncover new applications and therapies that can arise from plasma components. However, challenges such as regulatory issues and competition from alternative therapies exist and could impact the pace of growth.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Plasma Fractionation Market Product Type Insights Â
The Plasma Fractionation Market is experiencing significant growth, projected to reach a market value of 23.66 USD Billion in 2024, driven by the increasing demand for plasma-derived therapies across various applications. The market is segmented into several product types, with Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors being the key categories.
Immunoglobulin holds a major share of the market due to its essential role in treating immunodeficiencies and autoimmune disorders. Albumin, with its critical applications in managing shock and burns, is also a dominant product type, demonstrating its importance in medical treatments globally.
Coagulation Factors are significant in the hemophilia treatment landscape, facilitating effective management of bleeding disorders. Protease Inhibitors
play a vital role in therapeutic applications, particularly in antiviral and anti-inflammatory treatments. The growth in this market segment is propelled by rising healthcare investments and technological advancements, bolstering the Plasma Fractionation Market data and statistics. However, the market faces challenges, including regulatory hurdles and fluctuating plasma supply, which may impact production and distribution.
Plasma Fractionation Market End User Insights Â
The Plasma Fractionation Market is set to experience significant growth with various end users playing crucial roles in shaping its landscape. By 2024, the market is expected to be valued at approximately 23.66 billion USD, reflecting the increasing reliance on plasma-derived therapeutics in healthcare.
Hospitals serve as key players in this segment, leveraging plasma fractionation products for patients requiring immunoglobulins and clotting factor treatments, thus enhancing patient recovery and care standards.
Ambulatory Surgical Centers, known for their emphasis on outpatient procedures, also benefit from the availability of plasma therapies, ensuring effective treatments while optimizing operational efficiencies.
Blood Banks are fundamental to this market as they are responsible for collecting and processing plasma, ensuring a steady supply for various applications in medicine.
Pharmaceutical Companies dominate this segment by developing and manufacturing advanced plasma-derived medicines, contributing significantly to the Plasma Fractionation Market revenue.
These factors collectively highlight the diverse applications and the importance of each end user, driving the market towards substantial growth amidst evolving healthcare demands.
Plasma Fractionation Market Technology Insights Â
The Plasma Fractionation Market within the Technology segment is a crucial area, expected to reach a valuation of 23.66 billion USD by 2024. This market encompasses various techniques essential for the separation and purification of plasma proteins, with methods such as Centrifugation, Chromatography, Precipitation, and Filtration playing significant roles.
Centrifugation is widely utilized for its efficiency in separating components based on density, while Chromatography enhances the purity of plasma derivatives, making it a preferred choice in Research and Development.
Precipitation offers a cost-effective solution for isolating proteins, and Filtration provides a reliable method for removing impurities. These techniques not only contribute to the efficacy of plasma treatments but also drive advancements in therapeutic applications worldwide.
The market growth stems from an increasing demand for clotting factor concentrates and immunoglobulins, facilitating improved patient outcomes and addressing critical health challenges globally. As a result, the exploration of innovative technologies in this segment promises to elevate the standards of healthcare solutions derived from plasma fractionation.
Plasma Fractionation Market Regional Insights Â
The Plasma Fractionation Market showcases a diverse regional landscape, with significant contributions from various areas. In 2024, North America holds a majority holding with a valuation of 10.5 USD Billion, growing to 16.5 USD Billion by 2035. This dominance is driven by advanced healthcare infrastructure and increased demand for immunoglobulins.
Europe follows with a valuation of 6.5 USD Billion in 2024, reflecting a strong focus on Research and Development of plasma-derived therapies, expected to reach 10.0 USD Billion in 2035. South America is valued at 2.0 USD Billion in 2024, highlighting a growing interest in plasma products for treating diverse medical conditions.
Asia Pacific, with a valuation of 4.0 USD Billion in 2024, is anticipated to grow to 6.5 USD Billion by 2035, benefiting from expanding healthcare initiatives and population growth.
The Middle East and Africa segment, although relatively smaller at 0.66 USD Billion in 2024, is forecasted to rise to 1.5 USD Billion by 2035, driven by increasing awareness of plasma therapies.
Overall, the Plasma Fractionation Market data indicates significant growth potential across these regions, influenced by innovations in treatment options and expanding healthcare access.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Plasma Fractionation Market Key Players and Competitive Insights
The Plasma Fractionation Market has witnessed significant growth over recent years, driven by the increasing demand for plasma-derived therapies and the rising prevalence of various disorders such as hemophilia, immune deficiencies, and certain cancers.
This market is characterized by the presence of numerous key players, each striving to enhance their product offerings and expand their market share.
Competitive insights into this market reveal a landscape where innovation, strategic partnerships, and regulatory considerations play vital roles. Companies are focusing on research and development to improve existing products, while also exploring new therapeutic areas to address unmet medical needs.
Additionally, the market is experiencing consolidation through mergers and acquisitions as organizations aim to leverage synergies and streamline their operations.
LFB Group has established itself as a prominent player in the Plasma Fractionation Market through its emphasis on high-quality products and patient-centric solutions. The company benefits from its strong research and development capabilities, allowing it to introduce innovative plasma-derived therapies that meet the increasing global healthcare demands.
LFB Group's market presence is bolstered by its commitment to safety and efficacy, which resonates well with healthcare providers and patients alike.
The organization has developed a wide range of immunoglobulin and clotting factor products that cater to various therapeutic needs, making it a trusted name within the industry. Its collaborations with academic institutions and healthcare organizations further enhance its competitive position, emphasizing its role as a leader in providing specialized plasma-derived therapies globally.
Takeda Pharmaceutical is another key participant in the Plasma Fractionation Market, recognized for its extensive portfolio of biologics and plasma-derived therapies. The company offers a range of products, including immunoglobulins, clotting factors, and other therapeutic proteins, which serve various medical conditions.
Takeda's strength lies in its robust global presence, allowing it to reach a wide patient population and address local healthcare challenges effectively. With a strong focus on research and strategic partnerships, Takeda is actively engaged in mergers and acquisitions to enhance its technological capabilities and expand its product offerings.
These initiatives not only bolster its market position but also promote innovation in plasma fractionation technologies. The company’s commitment to patient access and improving health outcomes further solidifies its standing as a leader in the global market for plasma-derived therapies, enhancing its competitiveness in this dynamic industry.
Key Companies in the Plasma Fractionation Market Include
- LFB Group
- Takeda Pharmaceutical
- Octapharma
- Grifols
- Popharma
- ADMA Biologics
- Baxter International
- Biotest AG
- CSL Behring
- Indian Immunologicals
- Hualan Biological Engineering
- Prothena Corporation
- Shire
- Kedrion Biopharma
Plasma Fractionation Market Industry Developments
Significant news developments in the Plasma Fractionation Market include accelerated growth driven by increasing demand for immunoglobulin therapies and advancements in plasma-derived products. Companies like Grifols and CSL Behring are enhancing their production capabilities through investments in new facilities and technology.
In October 2023, Takeda Pharmaceutical announced plans to expand its manufacturing footprint in response to heightened demand, illustrating the competitive landscape.
Recent mergers and acquisitions have also shaped the industry; for instance, in September 2023, ADMA Biologics finalized its acquisition of a specialized plasma collection center to strengthen its supply chain.
Additionally, in December 2022, Octapharma and Hualan Biological Engineering formed a collaborative agreement to enhance production efficiency, indicating strategic alliances within the sector.
Moreover, technological advancements in plasma fractionation processes are improving yield and reducing costs, benefiting companies like Emergent BioSolutions and Biotest AG.
The overall market valuation continues to grow as consumer awareness of plasma-derived therapies rises, with emerging markets contributing to increasing investments. This growth trend emphasizes the importance of operational excellence and innovation in the industry's future endeavors while navigating regulatory landscapes in various global regions.
Plasma Fractionation Market Segmentation Insights
Plasma Fractionation Market Application Outlook
- Neurology
- Hematology
- General Medicine
- Immunology
Plasma Fractionation Market Product Type Outlook
- Immunoglobulin
- Albumin
- Coagulation Factors
- Protease Inhibitors
Plasma Fractionation Market End User Outlook
- Hospitals
- Ambulatory Surgical Centers
- Blood Banks
- Pharmaceutical Companies
Plasma Fractionation Market Technology Outlook
- Centrifugation
- Chromatography
- Precipitation
- Filtration
Plasma Fractionation Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and AfricaÂ
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
22.7(USD Billion)
|
|
Market Size 2024
|
23.66(USD Billion)
|
|
Market Size 2035
|
37.5(USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
4.28% (2025 - 2035)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2024
|
|
Market Forecast Period
|
2025 - 2035
|
|
Historical Data
|
2019 - 2024
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
LFB Group, Takeda Pharmaceutical, Octapharma, Grifols, Popharma, ADMA Biologics, Baxter International, Biotest AG, CSL Behring, Indian Immunologicals, Hualan Biological Engineering, Prothena Corporation, Shire, Kedrion Biopharma
|
|
Segments Covered
|
Application, Product Type, End User, Technology, Regional
|
|
Key Market Opportunities
|
Rising demand for immunoglobulins, Increasing prevalence of bleeding disorders, Expanding applications in therapeutics, Growth in aging population, Advancements in fractionation technologies
|
|
Key Market Dynamics
|
Rising demand for immunoglobulin therapies, Increasing prevalence of bleeding disorders, Technological advancements in fractionation, Growing geriatric population, Expanding pharmaceutical applications of plasma products
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Plasma Fractionation Market Highlights:
Frequently Asked Questions (FAQ):
The Plasma Fractionation Market was valued at 23.66 billion USD in 2024.
By 2035, the Plasma Fractionation Market is anticipated to reach a value of 37.5 billion USD.
The Plasma Fractionation Market is projected to have a CAGR of 4.28% from 2025 to 2035.
North America was dominated the Plasma Fractionation Market with a value of 10.5 billion USD in 2024.
In 2035, the North American market is projected to grow to 16.5 billion USD.
General Medicine had the highest market value at 8.9 billion USD in 2024.
The Hematology application segment is anticipated to reach a market size of 10.5 billion USD by 2035.
Major players include LFB Group, Takeda Pharmaceutical, Octapharma, Grifols, and CSL Behring.
The Immunology application segment was the market size of 2.46 billion USD in 2024.
The Asia Pacific region is expected to reach a market size of 6.5 billion USD by 2035.
